Ann: December Quarterly Activity and Cashflow Report, page-23

"The Company experienced unexpected operational and logistics delays",... and as a result of the brilliance of our management and staff to screw up something as fundamental as this, they have been rewarded by meeting all the criteria required to exercise their "performance rights".

"including damage to some of the initial samples sent from MGC Derma’s manufacturing facility, resulting in a delay to receipt of the $1 million deposit, as recently announced"..... So what can go wrong with oils? Can anyone explain how their samples could have been damaged? Were they contaminated? another reason to be awarded performance rights no doubt for sheer incompetence.

"Replacement and additional bulk samples, including a new formulation were subsequently dispatched during December and January 2018. Once Varm Cosmo completes testing of these new bulk samples, which is now underway, and they finalise their commercial order, receipt of the $1 million deposit is expected shortly"....so why wasn't the satisfactory testing of the bulk samples, being a condition of payment, disclosed in the initial release to the market?